CONTEXT: Optimal ages of breast cancer screening cessation remain uncertain.
B
reast cancer is largely a disease of old age, 1 with almost 50% of new cases and nearly two thirds of deaths occurring among the 13% of the female population that is aged 65 or more. 2 By the year 2030, 1 in 5 women will be 65 years of age or older (hereinafter referred to as ''older women''). 3 This ''graying of America'' 4 is expected to result in a large increase in the absolute number of breast cancer cases among older women. 5 However, the benefits, costs, 6, 7 and potential harms 8 of breast cancer screening for these older women 9 and the optimal ages of screening cessation 6 remain uncertain, owing to the interplay of competing age-related factors, including comorbidity, [10] [11] [12] mammography sensitivity, 13, 14 tumor characteristics, 1, [15] [16] [17] deviations from treatment guidelines, 18 and morbidity associated with breast cancer and its treatments. 19, 20 There is limited research addressing selected components of the balance between screening benefits, harms, and costs. For instance, Rich and Black used average age-specific mortality and estimated that 80-year-olds who stop screening would forego a maximum of 5 days of life. 21 However, this represents an average of days lost for women who develop breast cancer and the vast majority of women who do not, and does not include costs. In another study, Walter and Covinsky refined this approach by estimating benefits based on life expectancy distributions. 22 Kerlikowske et al. 6 developed a rigorous model to estimate costs and benefits by level of risk, but did not consider age-related variations in tumor biology or underlying health status.
In this paper, we used a simulation model that incorporates differences in tumor biology and emulates the effects of ''physiological age,'' or life expectancy to address the question of optimal timing of cessation of screening in older populations.
METHODS
We used an event-driven continuous time Monte Carlo simulation model 23 of the natural history of breast cancer to evaluate the costs, harms, and benefits associated with differing ages of screening cessation. Beginning at age 50, we compare biennial screening over the entire life span versus cessation of screening at age 70 or 79 years using average population mortality. We also evaluate outcomes using life expectancy as a proxy for physiologic age. We calculate incremental cost-effectiveness ratios, where the additional costs of a strategy, divided by the added savings in life years, are compared to the next least expensive effective strategy. 24 We do not include a ''no screening'' strategy because current recommendations include screening for women age 50 to 70. Investments in screening programs yield future savings in costs and lives. Discounting adjusts these future costs and outcomes to current values. Thus, all costs and effects are discounted at 3%. 24 Each strategy is examined by generating 250,000 simulated patients, a sample size chosen to ensure that the standard error of the difference in estimated population life expectancy between screening strategies would be less than 2 days. Finally, we simulated the life history of the ''same'' woman under all 3 screening strategies (stop at age 70, 79, screen for a lifetime). This ''matched'' approach decreases the standard errors and improves the precision of estimation of the differences between the strategies and maximizes computer resource efficiency. 25 
Model Overview
The model begins with a hypothetical cohort of women aged 50 and randomly assigns dates of death, preclinical and symptomatic breast cancer incidence, and uptake of first and subsequent screening mammograms. Women who are destined to get breast cancer are assigned a date at which symptomatic illness will present (clinical presentation). The stage of clinical presentation is selected randomly from age-specific distributions in unscreened women. If the tumor gets screen detected before this time (a true positive screen), a new stage is calculated using Bayes' theorem with a prior distribution taken from screened breast cancer incidence rates and a conditional distribution calculated from the rates of progression through the stages (in situ, local, regional, and distant). When women develop breast cancer, they are also randomly assigned an estrogen receptor (ER) status. Treatment is randomly selected based on current patterns of care, given age, stage at presentation, and ER status. Survival is randomly assigned based on age, stage, ER status, and treatment. We use survival obtainable in clinical trials as our base case; general breast cancer population survival as reported to the Surveillance, Epidemiology, and End Results (SEER) registry is used in sensitivity analyses. For women who do not develop cancer, the probability of a false positive mammogram is based on the age-specific specificity of mammography and the number of mammograms received between age 50 and the date of death or cessation of screening.
Model Assumptions
We used differences in the distribution of ER status as a proxy for age-related differences in prognostic tumor markers. 15, 16, 26 We make the simplifying assumption that lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS) have the same history and survival. Because the survival data we used were based on 15 years of clinical trial follow-up, we assumed that women with carcinoma in situ that was destined to progress to invasive disease or those with local stage who survived for 15 years without recurrence would have survival after that time that was similar to their age-matched nonbreast cancer cohort. Survival for women with local disease who were alive with recurrent disease at 15 years, or women with regional disease surviving 15 years was estimated using a declining exponential approximation of life expectancy. 27, 28 Given the truncation of observations for many women with distant disease, survival beyond the period of observation was estimated using SEER data. 29 We also assumed that screen and clinically detected cancers have the same survival, all other factors being equal. Finally, we assumed that all women comply with treatment.
Model Parameters
To estimate the probability of all costs and events in the model, we reviewed the medical literature to abstract the best data applicable to U.S. women. 30 All parameters are summarized in Tables 1  15, 29,31-40 and 2.
41-51
Disease Natural History. Age-specific incidence rates were estimated from SEER data. 29 Life Expectancy. The average annual probability of non-breast cancer death at each age was abstracted from life tables (''chronological age''). 52 In addition, to capture the within age variability in survival, we developed a synthetic life curve based on quartiles of life expectancy. These quartiles roughly correlate with self-reported general health 22, 52, 53 and are a proxy for ''physiologic age.'' For women with breast cancer, we used pooled data from 13 National Surgical Adjuvant Breast and Bowel Project (NSABP) trials among approximately 20,000 breast cancer patients to estimate 15-year survival by stage, treatment, age, and ER status. [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] Women participating in trials, especially those with regional disease, generally have higher than average survival (''idealized treatment and survival''), 67 giving resulted biased against screening. That is, the better treatment is, the lower the benefits of down staging disease via screening. We tested alternative community survival rates as reported to SEER in sensitivity analyses.
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Utilities. We presented our base case results using life years saved (LYS). 6 We examined the impact of estimated utilities in sensitivity analyses: without cancer .95, treatment for DCIS .87, treatment for local and regional disease .84, treatment for distant disease .55, surviving cancer .93, and living with metastatic disease as .55. Utilities for treatment were applied for 1 year after diagnosis.
Costs. We included medical (consumable supplies, personnel, laboratory, and procedure costs) and nonmedical (patient time costs) direct costs in year 2000 dollars (Table 2) . 49 Mammography costs were based on a microcosting approach using Medicare data for the components. 42, 68 The costs of cancer diagnosis and initial treatment, continuing care (including recurrences), and terminal care were estimated from linked SEER-Medicare reimbursement data from 1990 to 1999.
44,50 We assumed that Medicare reimbursements closely approximate societal costs. 68 Sensitivity Analyses. We varied individual parameters and combinations of parameters over reasonable ranges to examine the robustness of the model results under a variety of realistic conditions.
Model Validation. The technical programming accuracy was verified using ''pseudo-input'' designed to test the model under hypothetical conditions in which the results should be obvious. Our scientific advisors reviewed face and clinical validity.
Role of the Funding Source. The funding agencies had no role in data analysis, interpretation of results, or decisions to publish the results.
RESULTS
Over a lifetime, the model estimates that women have a 7% chance of having cancer diagnosed. At baseline screening rates of 73%, a program of biennial screening beginning at age 50 results in each woman undergoing an average of 15 mammograms in her lifetime, with a 66% cumulative risk of having a false positive screening result in this period. Regular biennial screening from age 50 to age 70 detects 90.9% of all lifetime cases, and continuing to age 79 captures 94.2% of these cases. Extending screening to age 79 or for a lifetime results in a larger proportion of cases being diagnosed as carcinoma in situ and local stage than more advanced stages (Fig. 1) . Screening does not result in significant overdiagnosis (not shown).
Compared to stopping screening at age 70, extending screening to age 79 saves 2.4 additional days of life per woman (undiscounted) for the entire population. Among women destined to develop breast cancer, screening to age 79 saves an additional 24.9 days of life per woman. The incremental cost of this added screening is $82,063 per LYS, compared to stopping screening at age 70. This result is obtained in a population where the average life expectancy is 9.5 years at age 79.
Further extending screening from age 79 to lifetime screening saves proportionally fewer days: 1.1 additional days across the population and 12 added days for cases, and is very expensive for the remaining increases in life saved ($151,434 per LYS) ( Table 3) . Ã Women reported as unknown stage were distributed as follows: 50% as regional and 50% as distant based on survival.
Chemo, chemotherapy; BCS, breast-conserving therapy; MST, mastectomy; RT, radiation therapy; DCIS, ductal carcinoma in situ.
These results are largely dependent on competing mortality. Thus, if screening is limited to women in the top 25% of life expectancy, then cost-effectiveness improves, and the cost of screening to age 79 decreases to $57,934 per LYS in a population of women who have an average life expectancy of 14.6 years at age 79. Screening these women without an upper age limit costs $126,629 (Table 4) . The initial phase of care includes all costs incurred by breast cancer patients for the 12-month period following the date of diagnosis (e.g., initial diagnostic evaluation and staging, hospitalizations and surgery, and any adjuvant chemotherapy, medical visits, and laboratory procedures).
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‰ The continuing care phase includes all costs incurred by breast cancer patients after the initial phase up to the 12 months prior to death (e.g., medical visits for surveillance, treatment of recurrences, hospitalizations, mammograms, and laboratory procedures, etc).
k Terminal care costs refer to all costs incurred by breast cancer patients in the last 12 months of life (e.g., hospitalizations, chemotherapy, laboratory procedures, and medical visits).
z Patient time costs were calculated based on estimated time valued at current average U.S. wage rates, even though many older women are not in the workforce. 51 # Because Medicare does not cover tamoxifen, we added these costs for estrogen receptor-positive women. Also, because rates of nonhormonal chemotherapy are low in older women, we added these costs to the initial care SEER-Medicare phase-specific costs for women who receive this therapy in the simulation. BCS, breast-conserving treatment; RAD, radiation therapy; MRM, modified radical mastectomy; DCIS, ductal carcinoma in situ.
Sensitivity Analysis
Under certain circumstances, continuing to screen past chronological age 79 may be reasonable (Table 5 ). For example, if screening is targeted at women at high risk of cancer (twice the population average, roughly corresponding to having a firstdegree relative with breast cancer), 69 then screening to age 79, compared to age 70, costs substantially less than screening the entire population ($62,842 for high-risk vs $82,063 per LYS for all women), and screening over a lifetime approaches a more reasonable level ($112,094). If treatment and survival is closer to that observed in SE-ER than in clinical trials, then the stage shifts observed with screening lead to greater savings in life years, especially for women diagnosed with regional cancer. In this situation, it becomes more cost-effective to continue screening until age 79 ($40,629 per LYS) than in the base case. If treatment and survival are similar to that observed in SEER and screening after age 70 is limited to women with the top 25% of life expectancies, then screening is very cost-effective, even without an upper age limit, costing $50,643 per LYS for lifetime screening compared to stopping at age 70.
If survival is quality adjusted, on average, screening should stop at age 70. This finding is the result of 2 facts: 1) being treated and living with the knowledge of cancer lowers quality of life in the years that are gained as ''lead time,'' or the earlier diagnosis of cancer without an improvement in survival, and 2) that lead time is fairly long relative to the true increase in life gained from screening. There are a few exceptions to this conclusion. Even if estimated quality-adjusted survival is considered, it remains cost-effective to screen all women until 79 if survival follows usual patterns of care (vs ''idealized'' care in RCT settings; $71,756 per quality-adjusted life year (QALY)). It may also be considered cost-effective to screen women with the highest life expectancies (top 25%) without an upper age limit when there is nonideal survival ($98,673 per QALY).
Changes in other parameters do not change the conclusions. Screening low-risk women (with one half the average risk) is very expensive. Screening annually is also very expensive and does not generate sufficient savings to justify screening beyond age 70. If women value present years of life to a much greater extent than future years (i.e., have a high discount rate for the future), then screening beyond age 70 is also extremely expensive (Table 5) .
If breast cancer is a slower growing disease in older women than the average modeled in our base case, then there is less new disease that would become clinically apparent within women's lifetimes, so that screening has fewer benefits and the cost-effectiveness decreases. In this situation, our results indicate that screening should stop at age 70, or be performed at less frequent intervals. If, on the other hand, disease progresses more rapidly in older ages than the average modeled in our base case, then biennial screening will miss more cases and screening beyond age 70 is also not cost-effective (Table 5 ). In the latter situation, annual screening would become more cost-effective than with average base case dwell times (not shown). Varying the test sensitivity or costs does not change the conclusions and has minimal impact on the absolute costeffectiveness ratios (not shown).
DISCUSSION
This is the first study to explicitly consider a proxy for women's physiologic age as well as age-specific disease natural history in making breast cancer screening decisions for older women. At a threshold of cost-effectiveness of $80,000, our results suggest that it is cost-effective to conduct biennial screening until age 79. If a threshold of $60,000 is considered cost-effective, then screening to age 79 is only cost-effective if limited to women with life expectancies in the top quartile for their ages. These conclusions are based on the assumption that all older women with breast cancer have survival comparable to that seen in clinical trials. If treatment patterns are not ideal and survival is lower, as is the case at present, then screening has greater benefits, and it might be appropriate to continue screening without an upper age limit.
The result that screening benefits are greatest in women with the longest life expectancy is intuitively obvious. However, clinicians often underestimate older women's life expectancy, 70 and there is considerable heterogeneity in health and functioning. 22 Using a threshold for cost-effectiveness of $80,000 per LYS, a figure many would consider reasonable by current standards for screening, 6, 71 it is cost-effective to screen women with a life expectancy of 9.5 years. This value can be expected for 75% of 79-year-olds, about 50% of 80-year-olds, and 25% of 85-year-olds. 22 Therefore, one practical implication of our analysis is that simple methods to determine life expectancy in clinical settings could aid screening decisions for older women.
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Our results imply that prevailing treatment patterns (and the resultant survival) play a central role in screening decisions. However, optimal treatment of older women remains controversial, largely as a result of a paucity of primary data in this age group, with only 1% to 2% of older women treated in clinical trials, 67 and only 30% to 40% receiving some chemotherapy. 72, 73 If such patterns continue, then our model suggests that screening may be beneficial beyond age 79, especially for the healthiest women. If we could accurately triage women according to risk of developing breast cancer, then it is also reasonable to screen to age 79, and perhaps for life among high-risk women. This finding confirms results of an earlier model that showed that screening older high-risk women (based on bone mineral density, a proxy for estrogen exposure) was cost-effective until age 79, costing $66,773 per life year saved, compared to stopping at age 69. That result is very similar to our result of $62,843 per year of life saved for screening high-risk women (based on family history) to age 79 (vs stopping at age 70).
We found that from a societal perspective, screening is too expensive relative to its benefits to be offered on an annual basis to average-risk and average-health women after age 70. However, optimal intervals depend on disease biology, particularly the time from stages that are detectable preclinically to stages that present clinically with symptoms. For instance, if tumors grow more slowly in older women, with a preclinical detectable period of 6.2 years, 74 then screening intervals might logically be extended from every 2 to every 3 to 5 years. The benefits of screening older women have been noted in other studies 75, 76 and recent reviews of cost-effectiveness analyses have concluded that biennial screening after age 65 is generally cost-effective, 77 especially in the absence of major comorbidity limiting life expectancy. 78 This is very similar to our finding that cost-effectiveness is most favorable for women in the top 25% of life expectancy for their age group. When caring for asymptomatic populations, it is important to consider the harms as well as the benefits of screening. If screening is extended from age 70 to 79, or for a lifetime, then women have an increased risk of having a false positive result. 8 One way to decrease the number of false positive exams is to extend the screening interval among older women. This would decrease costs, and, if tumors are slow growing, still maintain benefits. Women who are screen detected live with cancer and treatment consequences for a longer period of Our analysis has several important strengths, including use of current standards for cost-effectiveness analyses, 24 developing a paradigm for basing decisions on physiological as opposed to chronological age, estimation of age-specific tumor biology, a robust model, and assessment of the impact of uncertain parameters. Despite these strengths, there are several issues that should be considered when interpreting our results. First, we used life expectancy corresponding to quartiles of health and age to measure the probability of death as a proxy for physiological age. Clearly, data that link direct measurement of physiological reserve to clinical assessments of health status and life expectancy would be invaluable in individual decision making. In the interim, using life expectancy based on individual health conditions or self-reported health, rather than average U.S. age-specific life expectancies, may be a better indicator than age per se for use in clinical practice.
Second, while our model goes beyond many prior models of screening, our estimates of age-specific tumor natural history are fairly crude and limited by the relative paucity of data for this age group. Also, within any age group, breast cancer is a heterogeneous disease with variability in aggressiveness and probability of disease progression.
Next, our results must also be considered in the context of the current controversies about the effectiveness of mammography.
9,79 Our model does not make a direct assumption about the impact of mammography on breast cancer mortality. Rather, we rely on observed stage distributions among screened and unscreened older populations to calculate screening benefits. Also, within each stage, we assumed similar survival for mammographically detected and non-screen-detected cancers. This assumption biases results against screening benefits. Fourth, we restricted the screening intervals evaluated to those currently under consideration or in use in the United States. If it becomes generally acceptable to extend screening intervals to every 3 to 5 years after a certain age, then our model could be used to estimate the potential costs savings relative to any losses in benefits.
In addition, we used Medicare reimbursements as the single best source of costs for all analyses, while our base survival estimates were derived from clinical trials. Costs in clinical trials may be higher or lower than average, depending on intensity and efficiency of care. At present, we are not aware of any data that compare treatment costs for older women off and on clinical trials. Our model also does not capture the effects of distress associated with a false positive screen, 80, 81 but given the transient nature of this adverse event, it is not likely to alter our conclusions. Finally, our results may only be generalizable to U.S. screening policies. Breast cancer is largely a disease of old age. Older women are a rapidly growing segment of the U.S. population and will be very heterogeneous in their health and functioning. We recommend that policymakers and clinicians explicitly consider life expectancy, or ''physiological age,'' how aggressively older women with cancer will be treated, and women's preferences in making screening decisions affecting older women.
